Tonix sets Tonmya WAC at $1,860/month; appoints Ganesh Kamath as Head of Market Access

Tonix Pharmaceuticals Holding Corp.

Tonmya (cyclobenzaprine HCl sublingual tablets) approved Aug 15, 2025 for fibromyalgia; launch expected Q4 2025.
Wholesale acquisition cost (WAC) set at $1,860/month for 60-count supply; geriatric/mild hepatic: $930/month for 30-count.
Ganesh Kamath appointed Head of Market Access effective Sept 29, 2025; brings 25+ years experience from Bayer, Hutchmed, CuriaGlobal.
Kamath will lead pricing, contracting, and payer engagement for Tonmya launch and pipeline.
First new fibromyalgia prescription therapy in over 15 years; Tonix also markets two acute migraine treatments.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.